#Sweden #Lund #Hansa Biopharma #IDEFIRIX #kidney transplantation

Hansa Biopharma's Promising Study Results for Idefirix in Kidney Transplantation

Hansa Biopharma AB, a noted biopharmaceutical company, has recently unveiled positive results from its European post-authorization efficacy study known as the 20-HMedIdeS-19. This study assessed the efficacy of Idefirix (imlifidase) for highly sensitized patients undergoing HLA-incompatible kidney transplantation. With an impressive graft failure-free survival rate of 90% after one year, these results pave the way for the full marketing authorization submission to the European Medicines Agency (EMA) planned for Q4 2026.

Renée Aguiar-Lucander, the CEO of Hansa Biopharma, expressed that these results signify a crucial milestone for both the company and Idefirix. The one-year graft failure-free survival witnessed in this highly sensitized patient cohort reconfirms the clinical advantages of Idefirix, reinforcing its therapeutic impact in the realm of kidney transplantation. The observed efficacy outcomes align with the safety profile established in earlier clinical explorations. This successful post-authorization study stance supports Hansa's forthcoming application for complete marketing authorization.

The Significance of Idefirix

Idefirix plays a pivotal role in kidney transplantation, particularly for patients with high immunological sensitization who often struggle to find compatible donor organs. In Europe, these highly sensitized individuals have faced prolonged waiting periods, sometimes extended indefinitely. Idefirix emerges as a transformative option, ensuring they have a legitimate chance at receiving transplanted kidneys.

Dr. Tomas Lorant, an associate professor and transplant surgeon at Uppsala University, who coordinated the trial, noted how imlifidase plays a pivotal role in enhancing transplantation care. By enabling successful kidney transplants for this vulnerable patient population, Idefirix has proven its worth in transforming lives – giving patients a renewed opportunity for health that would have otherwise remained elusive.

Since its conditional approval in the European Union, Idefirix has garnered attention and hope as a desensitization solution for adults who previously faced hurdles due to positive crossmatch results against potential deceased donors. The PAES study involved 51 patients distributed across 22 transplant centers in 11 countries in the EU and the UK, further substantiating the promising outlook for the treatment protocol.

In terms of performance metrics, not only did the trial achieve its primary objective, but it also yielded substantial secondary findings. Following treatment with Idefirix, the study revealed a mean estimated glomerular filtration rate (eGFR) of 52.4 mL/min/1.73 m², a graft survival rate of 92%, and a patient survival rate of 98% at the 12-month mark. These statistics underscore that the administration of Idefirix not only sustains graft health but also enhances overall patient wellbeing.

Looking Ahead: Regulatory Applications and Future Impact

With the post-authorization efficacy requirements fulfilled, Hansa plans to apply for full marketing authorization with the EMA by the end of this year. The ongoing commitment to ensure Idefirix is made accessible to those in severe need speaks to Hansa Biopharma's mission to significantly enhance therapeutic options in transplantation.

The results from the PAES will be shared at an upcoming medical congress, which will shed further light on the potential of Idefirix. For those monitoring the developments in kidney transplantation therapies, this study signals a notable advancement – one that underscores the necessary integration of innovative solutions tailored for patients with nuanced, specific immunological challenges.

Interest in Idefirix is also reflected across global pathways. The FDA has received Hansa's Biologics License Application for imlifidase back in February 2026, with designated action dates anticipated later this year.

In summary, Hansa Biopharma is not just advancing biopharmaceutical research but is dramatically altering the landscape for kidney transplantations, providing hope to countless individuals navigating through the uncertainties of organ transplant compatibility.